Author

Udai Banerji

Royal Marsden NHS Foundation TrustORCID 0000-0003-1503-3123Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:simulation· 1 Approach:statistical model· 1

Frequent Co-Authors

Ahmet AcariD· 1 shared Alvaro Ingles GarcesiD· 1 shared Amna Z. ShahiD· 1 shared Anderson Wang· 1 shared Andrea SottorivaiD· 1 shared Ashley NichollsiD· 1 shared Charlie George BarkeriD· 1 shared Chris Wong· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahmet AcarORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistrybioRxivPreprintSep 24, 2026

Cellular uptake of folate-olaparib conjugates via folate receptor-mediated endocytosis: Potential for selective delivery of DNA damage response inhibitors into tumour cells

Vassilios Bavetsias, Lisa Pickard, Sara Díaz-Sánchez…·Udai Banerji

This paper develops folate-olaparib conjugates that selectively enter FR-overexpressing tumor cells via endocytosis and inhibit PARylation.

DOI 10.64898/2026.09.23.752340

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 13, 2026

Inference of Cancer Drug Cross Resistance Using Only Single-Drug Exposure Data

Frederick J.H. Whiting, Ioanna Mavrommati, Ahmet Acar…·Trevor A. Graham

This paper identifies cross resistance between cancer drugs using single-drug exposure data, showing that high cross resistance reduces the effectiveness of switching between CDK4/6 inhibitors.

DOI 10.64898/2026.03.10.709822

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 7, 2025

Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico Modelling

Matthew A. Clarke, Charlie George Barker, Ashley Nicholls…·Jasmin Fisher

This paper develops an in silico model to predict personalized therapeutic combinations for NSCLC by simulating genetic profiles and testing drug combinations to overcome resistance.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky